KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Change in Account Payables (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Change in Account Payables for 8 consecutive years, with -$17000.0 as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 97.02% to -$17000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.1 million through Dec 2025, up 170.4% year-over-year, with the annual reading at $3.1 million for FY2025, 170.4% up from the prior year.
  • Change in Account Payables hit -$17000.0 in Q4 2025 for Castle Biosciences, down from $1.4 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $3.9 million in Q1 2023 to a low of -$2.2 million in Q3 2024.
  • Historically, Change in Account Payables has averaged $240650.0 across 5 years, with a median of -$28500.0 in 2021.
  • Biggest five-year swings in Change in Account Payables: tumbled 1935.71% in 2021 and later surged 1983.42% in 2023.
  • Year by year, Change in Account Payables stood at -$855000.0 in 2021, then crashed by 83.98% to -$1.6 million in 2022, then skyrocketed by 291.61% to $3.0 million in 2023, then crashed by 118.91% to -$570000.0 in 2024, then soared by 97.02% to -$17000.0 in 2025.
  • Business Quant data shows Change in Account Payables for CSTL at -$17000.0 in Q4 2025, $1.4 million in Q3 2025, and $1.1 million in Q2 2025.